1. Pink Sheet

Next-Gen CAR T & Novel SMA Drug Among New Entrants On EMA’s PRIME

Rare Pediatric Disease Drug & Multiple Myeloma Therapy Also Make The Grade

 
• By Neena Brizmohun

Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.

3D illustration of T cells attacking a cancer cell (CAR-T cell therapy) - Illustration
Autolus says its investigational treatment may overcome limitations of other CAR T-cell therapies • Source: Shutterstock

AUT01 (obecabtagene autoleucel), a next-generation CAR T-cell therapy that Autolus Therapeutics is developing to treat relapsed/refractory lymphocytic leukemia (ALL), has secured a place on the European Medicines Agency’s PRIME (priority medicines) scheme.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.